(Q64223140)
Statements
RELIEF (English)
0 references
Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis (English)
0 references
31 May 2014
0 references
30 April 2016
0 references
200
0 references
18 year
0 references
60 year
0 references